UK-based biopharmaceutical company AMO Pharma and US-based biopharmaceutical company Ranedis Pharmaceuticals have signed an agreement to collaborate for the further development of drug candidate RND-001.
The drug is targeted at treating rare genetic diseases such as certain lysosomal storage disorders and other diseases affecting the central nervous system.
The agreement also gives AMO Pharma an exclusive option to acquire the worldwide rights to the drug during the collaboration period.
UK-based drug discovery company C4X Discovery Holdings has raised £7m ($8.54m) in gross proceeds through the private placement of shares of its common stock.
The placement included 8.2 million shares priced at £0.85 ($1.04) a share, which represented a discount of 7.1% to its mid-market closing price on 13 March.
The proceeds are intended to be used primarily for strengthening the company’s balance sheet, expanding commercial capability and to supplement working capital.
OncoSec Medical has signed an agreement with a biotherapeutic company Inhibrx, under which the latter will use the former’s proprietary gene delivery technologies, research generator and proprietary applicators for pre-clinical discovery of antibodies.
Both companies involved in the transaction are based in the US.
Peloton Therapeutics has completed an optional tranche of series D financing round, under which it raised $22.2m.
The first series D financing round was completed in September 2016 and raised $52.4m for the company.
Based in the US, Peloton Therapeutics is a drug discovery and development company focused on cancer therapies.
US-based contract research company Charles River Laboratories International and Italian pharmaceutical company Chiesi Farmaceutici have extended their partnership for their integrated respiratory drug discovery programme.
The former will continue to provide its portfolio of integrated drug discovery capabilities to the latter to help identify and test its promising respiratory drug candidates for pre-clinical development.